<DOC>
	<DOCNO>NCT00921219</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic bioavailability profile ( rate amount absorption bloodstream ) test formulation Ivermectin solution 1 mg/ml market reference formulation Ivermectin 3 mg tablet take standard meal . The study design accordance EU Note Guidance Investigation Bioavailability Bioequivalence 2001 .</brief_summary>
	<brief_title>Ivermectin Solution Bioequivalence Study - With Food ( Repeat )</brief_title>
	<detailed_description>Ivermectin antiparasitic medicine ( i.e . medicine use eliminate parasitic worm ) oral administration , approve US country tablet form . A new liquid formulation ivermectin develop facilitate dosing . This single dose , randomise , crossover study healthy adult male female volunteer , dose take 20 minute standard breakfast . Doses separate washout period least 14 day . Twenty-one blood sample take volunteer 144 hour period . Concentrations Ivermectin plasma measure use validated chromatographic assay ( LC-MS/MS ) . Standard pharmacokinetic parameter obtain bioequivalence basis rate extent drug absorption assess .</detailed_description>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>Healthy male female volunteer Aged 18 50 year BMI &lt; /= 30 kg/m2 Weight 50 90 kg Nonsmokers , smoker fewer 10 cigarette per day Clinically normal medical history Clinically normal finding physical examination Clinically normal blood pressure ( &gt; /= 100/60 male ; &gt; /= 90/50 female ; &lt; /= 140/90 ) Electrocardiogram recording ( 12lead ) within normal range Clinically normal finding haematology clinical chemistry blood urine , show clinically insignificant deviation negative screen result ( within 14 day study start ) drug abuse , include opiate , cannabinoids , amphetamine , methamphetamine , benzodiazepine cocaine Negative HIV Hepatitis B C test ( within 14 day study start ) Appropriate use effective method contraception ( female volunteer ) Negative pregnancy test ( female volunteer ) Ability comprehend communicate effectively Investigator staff Ability give write informed consent Illness within 14 day start study Hospitalisation within 3 month start study ( discretion Investigator ) Participation clinical trial blood take within 16 week start study Participation clinical trial volume blood exceed 500 ml take within 12 month start study Donation blood plasma within 90 day start study Any indication current previous abuse alcohol , solvent drug Treatment full regular course medication 28 day start study proscribe medication 14 day start study Use alcohol study day within 24 hour prior commencement study period Intake grapefruit product within 7 day start study Intake methylxanthinecontaining beverage within 24 hour prior study period Intake quantity methylxanthine alcoholcontaining beverage , opinion Investigator abnormal ( habitually take 5 cup glass tea , coffee , cola , chocolate etc . per day habitually take 20 g alcohol/day ) Patient pregnant , lactating/breastfeeding ( female volunteer ) Diet , opinion Investigator , deviate normal diet ( e.g . vegan ) Patients reside area Africa know endemic Onchocerca volvulus ( onchocerciasis river blindness ) , wuchereria bancrofti ( lymphatic filariasis ) , Loa loa microfilaremic disease Patients know suspect intestinal helminth infection , Strongyloides stercoralis intestinal helminth Patients know hypersensitivity component Ivermectin product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>therapeutic equivalency</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>food</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>